智通财经APP讯，联邦制药(03933)发布公告，于2026年2月2日，本公司全资附属公司联邦生物科技(珠海横琴)有限公司(联邦生物科技)自主研发的1类创新药UBT251注射液关于合并肥胖的中重度阻塞性睡眠呼吸暂停(OSA)适应症获得中国国家药品监督管理局临床试验默示许可，受理号为CXHL2501306。
UBT251 注射液是联邦生物科技自主研发的多靶点多肽类受体激动剂，可通过作用于胰高血糖素样肽-1(GLP-1)受体、葡萄糖依赖性促胰岛素多肽(GIP)受体和胰高血糖素(GCG)受体降低血糖，抑制体重增加。以GLP-1类为代表的减重药物，有望填补OSA治疗领域大量未被满足的临床需求。
此外，UBT251 注射液的超重或肥胖、2 型糖尿病、代谢相关脂肪性肝炎及慢性肾脏病适应症已于中国开展II期临床研究。
作为中国首个化学合成GLP-1/GIP/GCG三靶点受体激动剂新药，UBT251助力本公司于该类药物研究领域占据重要地位。未来，本公司将持续致力于新产品研发，并重点提升在生物医药行业的竞争力及创造力，预期将为本公司及其股东创造更大收益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.